China Pharma Holdings Inc (CPHI) - Total Liabilities

Latest as of September 2025: $7.49 Million USD

Based on the latest financial reports, China Pharma Holdings Inc (CPHI) has total liabilities worth $7.49 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore China Pharma Holdings Inc annual equity growth to track the company's year-over-year net asset growth rate.

China Pharma Holdings Inc - Total Liabilities Trend (2001–2024)

This chart illustrates how China Pharma Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. See CPHI FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

China Pharma Holdings Inc Competitors by Total Liabilities

The table below lists competitors of China Pharma Holdings Inc ranked by their total liabilities.

Company Country Total Liabilities
Thrive Tribe Technologies Ltd
AU:1TT
Australia AU$659.69K
Chanson International Holding Class A Ordinary Shares
NASDAQ:CHSN
USA $25.77 Million
Fenbo Holdings Limited Ordinary Shares
NASDAQ:FEBO
USA $35.80 Million
NAYA Biosciences, Inc
NASDAQ:NAYA
USA $33.70 Million
PolyPlank publ AB
ST:POLY
Sweden Skr21.55 Million
Scout Security Ltd
AU:SCT
Australia AU$11.61 Million
John Wood Group PLC
LSE:WG
UK GBX3.24 Billion
Netcall plc
LSE:NET
UK GBX47.25 Million

Liability Composition Analysis (2001–2024)

This chart breaks down China Pharma Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CPHI stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.35 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.88 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.47 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how China Pharma Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for China Pharma Holdings Inc (2001–2024)

The table below shows the annual total liabilities of China Pharma Holdings Inc from 2001 to 2024.

Year Total Liabilities Change
2024-12-31 $7.14 Million -20.80%
2023-12-31 $9.01 Million -33.20%
2022-12-31 $13.49 Million -18.87%
2021-12-31 $16.63 Million +26.83%
2020-12-31 $13.11 Million +0.89%
2019-12-31 $13.00 Million -14.37%
2018-12-31 $15.18 Million -10.09%
2017-12-31 $16.88 Million -13.92%
2016-12-31 $19.61 Million -20.22%
2015-12-31 $24.58 Million -4.83%
2014-12-31 $25.83 Million +4.71%
2013-12-31 $24.67 Million +67.53%
2012-12-31 $14.72 Million +5.86%
2011-12-31 $13.91 Million +0.68%
2010-12-31 $13.81 Million +31.00%
2009-12-31 $10.54 Million +88.18%
2008-12-31 $5.60 Million +42.05%
2007-12-31 $3.94 Million -48.53%
2006-12-31 $7.66 Million +11103.95%
2005-12-31 $68.41K 0.00%
2004-12-31 $68.41K -93.38%
2003-12-31 $1.03 Million +4.09%
2002-12-31 $992.02K 0.00%
2001-12-31 $992.02K --

About China Pharma Holdings Inc

NYSE MKT:CPHI USA Drug Manufacturers - Specialty & Generic
Market Cap
$2.48 Million
Market Cap Rank
#29751 Global
#6002 in USA
Share Price
$0.76
Change (1 day)
-0.25%
52-Week Range
$0.52 - $2.00
All Time High
$64.00
About

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin inje… Read more